Arantxa Barandiarán Aizpurua

Arantxa Barandiarán Aizpurua

Auto-generated profile, based on publicly available information

Arantxa Barandiarán Aizpurua

Department of Cardiology, CARIM, Maastricht University Medical Centre , Maastricht

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
Jerremy WeertsJerremy Weerts
Jerremy Weerts
AAArantxa Barandiarán Aizpurua
Arantxa Barandiarán Aizpurua
MHMichiel T H M Henkens
Michiel T H M Henkens
ALAurore Lyon
Aurore Lyon
MMManouk J W van Mourik
Manouk J W van Mourik
CKChristian Knackstedt
Christian Knackstedt
This study assessed the prognostic implications of mechanical atrial dysfunction in heart failure with preserved ejection fraction (HFpEF) patients with different stages of atrial fibrillation (AF) in detail. HFpEF patients (n = 258) systemically underwent an extensive clinical characterization, including 24-h Holter monitoring and speckle-tracking echocardiography. Patients were categorized according to rhythm and stages of AF: 112 with no history of AF (no AF), 56 with paroxysmal AF (PAF), and 90 with sustained (persistent/permanent) AF (SAF). A progressive decrease in mechanical atrial function was seen: left atrial reservoir strain (LASr) 30.5 ± 10.5% (no AF), 22.3 ± 10.5% (PAF), and 13.9 ± 7.8% (SAF), P < 0.001. Independent predictors for lower LASr values were AF, absence of chronic obstructive pulmonary disease, higher N-terminal-pro hormone B-type natriuretic peptide, left atrial volume index, and relative wall thickness, lower left ventricular global longitudinal strain, and echocardiographic signs of elevated left ventricular filling pressure. LASr was an independent predictor of adverse outcome (hazard ratio per 1% decrease =1.049, 95% confidence interval 1.014–1.085, P = 0.006), whereas AF was not when the multivariable model included LASr. Moreover, LASr mediated the adverse outcome associated with AF in HFpEF (P = 0.008). Mechanical atrial dysfunction has a possible greater prognostic role in HFpEF compared to AF status alone. Mechanical atrial dysfunction is a predictor of adverse outcome independently of AF presence or stage, and may be an underlying mechanism (mediator) for the worse outcome associated with AF in HFpEF. This may suggest mechanical atrial dysfunction plays a crucial role in disease progression in HFpEF patients with AF, and possibly also in HFpEF patients without AF.

31 January 2021 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
AAArantxa Barandiarán Aizpurua
Arantxa Barandiarán Aizpurua
SWSandra Sanders-Van Wijk
Sandra Sanders-Van Wijk
HRHans-Peter Brunner-La Rocca
Hans-Peter Brunner-La Rocca
MHMichiel T.H.M. Henkens
Michiel T.H.M. Henkens
Jerremy WeertsJerremy Weerts
Jerremy Weerts
VEVanessa P.M. van Empel
Vanessa P.M. van Empel
Aims Whether and how iron deficiency (ID) impacts patients with heart failure (HF) with preserved ejection fraction (HFpEF) remain unclear. The aim of our study was to investigate the impact of ID on functional status, exercise capacity, and prognosis in HFpEF. Methods and results The study population consisted of 300 HFpEF patients. ID was defined as serum ferritin <100 μg/L or 100–300 μg/L and transferrin‐saturation <20%. Baseline functional status, quality of life (HADS score and EQ 5D index), 6 min walking test, echocardiography, and outcome (all‐cause mortality and combined all cause‐mortality and HF hospitalization) were evaluated. ID was found in 159 (53%) patients. Patients with ID had a worse prognosis with a higher combined endpoint of all‐cause mortality and HF hospitalization after 4 years of follow‐up (log rank = 0.008). Pulmonary hypertension, depression, and thyroid disease were more prevalent in the ID group. Multivariable analysis showed that ID was independently associated with body mass index (P = 0.003), pulmonary hypertension (P = 0.008), and thyroid disease (P = 0.01). Although patients with ID had a lower exercise capacity compared with patients without ID (393 m [294–455] vs. 344 m [260–441], P = 0.008), there was no significant correlation after multivariable correction for age, BMI, NT‐proBNP, DM, and depression. Conclusions Heart failure with preserved ejection fraction patients with ID have a worse prognosis and impaired exercise capacity compared with those without ID. However, although a trend was observed, after multivariable correction ID was no longer significantly associated with a reduced exercise capacity. This reflects that impaired exercise capacity in HFpEF is complex and seems multifactorial. Interestingly, pulmonary hypertension was an independent predictor of both ID and exercise capacity.

5 April 2025 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
NVNousjka P. A. Vranken
Nousjka P. A. Vranken
XLXinyu Li
Xinyu Li
HBHeleen Bouman
Heleen Bouman
SMSanne G. J. Mourmans
Sanne G. J. Mourmans
AAAnouk Achten
Anouk Achten
Jerremy WeertsJerremy Weerts
Jerremy Weerts
Background: Most patients with heart failure with preserved ejection fraction (HFpEF) have a metabolic phenotype in which comorbidities including diabetes mellitus play an important role. Factors related to impaired glucose metabolism, such as kidney disease, may contribute to adverse clinical events. Albuminuria is an early marker of kidney disease. We assessed the prevalence of impaired glucose metabolism and albuminuria in HFpEF over time, and evaluated its prognostic implications. Methods: Consecutive patients referred to our outpatient clinic and diagnosed with HFpEF between March 2015–November 2023 were included in this study. Patients with type 1 diabetes were excluded. Patients were stratified according to baseline glucose metabolism status (DM + for prediabetes and diabetes, or DM−) and albuminuria status (ALB+ or ALB− for albuminuria > 3.0 mg/mmol and normoalbuminuria, respectively). The primary outcome was a composite of HF hospitalizations (HFH) and all-cause mortality, and was analysed using multivariable-adjusted Cox-regression models. Results: Among 332 patients with HFpEF (median age 77 years; 67% female), 121 (36.4%) were classified as DM−/ALB−, 106 (31.9%) as DM+ /ALB−, 44 (13.3%) as DM−/ALB+, and 61 (18.4%) as DM+ /ALB+. Both baseline DM and ALB were independently associated with the primary outcome after approximately 3 years: adjusted hazard ratio (aHR) 1.93; 95% confidence interval (CI) 1.25–2.97 and 1.58; 95%CI 1.04–2.41, respectively. Patients in the DM+ /ALB+ group showed the highest risk (aHR 2.85; 95%CI 1.57–5.15). After one year, DM/ALB status was re-evaluated in 250 (75%) patients. New DM+ and ALB+ incidence was 3.9% and 22%in those at risk, respectively. Patients particularly changed ALB groups compared to baseline (n = 63, 25.2%); 27 (10.8%) patients recovered from albuminuria. At 3 years follow-up, the primary outcome mainly occurred in patients who consistently showed albuminuria (27.1%) or who recovered from albuminuria (22.2%), and less so in patients who developed albuminuria after one year (13.9%) or who remained free of albuminuria (8.6%) (p = 0.008). Conclusions: DM and albuminuria are prevalent in HFpEF at baseline, and re-evaluation one year later still reveals new diagnoses. Both factors are independently associated with adverse outcomes. Albuminuria at any time point remains predictive of adverse outcomes in HFpEF. Graphical Research insights: What is currently known about this topic?: Diabetes mellitus is an important cardiovascular risk factor in patients with HFpEF, contributing to disease progression and worse outcomes. Albuminuria is a prognostic marker in heart failure patients and more prevalent in patients with diabetes What is the key research question?: What is prevalence of impaired glucose metabolism and albuminuria in HFpEF over time and how does this translate to prognosis? What is new?: Both DM and albuminuria each independently associated with worse prognosis in HFpEF. Screening 1 year after HFpEF diagnosis yielded incidence rates of 3.9% and 10.8% for DM and prediabetes, respectively, and 22% for albuminuria. Albuminuria at any time point appeared prognostic in HFpEF, also when albuminuria recovered How might this study influence clinical practice?: Intermittent screening of HFpEF patients for abnormal glucose metabolism and albuminuria is warranted to optimize risk management

19 May 2025 in European Journal of Heart Failure
Verified
Journal Article
Open access
Jerremy WeertsJerremy Weerts
Jerremy Weerts
AAArantxa Barandiarán Aizpurua
Arantxa Barandiarán Aizpurua
RPRavi B. Patel
Ravi B. Patel
ABArno A. van de Bovenkamp
Arno A. van de Bovenkamp
HAHesam Amin
Hesam Amin
VEVanessa P.M. van Empel
Vanessa P.M. van Empel
Heart failure with preserved ejection fraction (HFpEF) is common but diagnosing it remains cumbersome and complex. Left atrial (LA) enlargement and dysfunction is an important pathologic marker in HFpEF. We evaluated whether LA measures and circulating natriuretic peptides (NPs) could simplify HFpEF diagnosis as a first step. A new, first-step diagnostic approach to rule in HFpEF is presented using LA volume indexed for height2 (LAViH2; cut-off >35.5 ml/m2 in sinus rhythm, or >38.6 ml/m2 in atrial fibrillation) and NPs (as per the HFA-PEFF major criterion). The LA/NP approach was derived from 443 patients with suspected of HFpEF (final diagnosis 84% HFpEF, 16% controls without heart failure), and validated in two independent cohorts (503 patients, 90% HFpEF; and 123 patients undergoing (exercise) right heart catheterization, 86% HFpEF). The LA/NP step identified 60% HFpEF patients with 88% specificity and 97% positive predictive value (PPV) (derivation cohort). Sequentially applying the LA/NP step, and if normal followed by either HFA-PEFF or H2FPEF algorithm, reduced intermediate HFpEF likelihood scores compared to starting with the algorithms, decreasing additional diagnostic needs for HFpEF diagnosis by 27% (HFA-PEFF) and 56% (H2FPEF). Validation cohorts confirmed the LA/NP approach (76-80% specificity, 92-97% PPV, and 21-57% reduction in intermediate scores). Replacing LAViH2 with LA reservoir strain showed comparable results. A first-step approach using enlarged LA volume and elevated NPs simplifies HFpEF diagnosis. This approach identifies most HFpEF patients with high specificity and substantially reduces the need for additional diagnostics by lowering intermediate HFA-PEFF or H2FPEF scores.

2 July 2025 in European Journal of Heart Failure
Verified
Journal Article
Open access
CGChrit B.G. Geraeds
Chrit B.G. Geraeds
ABAnke Bruninx
Anke Bruninx
ADAndré Dekker
André Dekker
AAArantxa Barandiarán Aizpurua
Arantxa Barandiarán Aizpurua
IBInigo Bermejo
Inigo Bermejo
HRHans-Peter Brunner-La Rocca
Hans-Peter Brunner-La Rocca
Aims: Loop diuretics are widely used in heart failure (HF) for symptom relief. Guidelines advise treating patients with the lowest possible dose of loop diuretics to maintain euvolaemia, based on expert opinion only. However, data on the safety of this practice are scarce. This analysis aims to investigate the clinical course after changing loop diuretics in stable HF patients. Methods and results: A post-hoc analysis from the TIME-CHF study was conducted in 622 patients. Daily loop diuretic doses were meticulously recorded, resulting in 11 035 dose evaluations assessed. The frequency of relevant events within 30 days (hospitalization, death, dose change) following an up-titration, down-titration, or no change in diuretic therapy was calculated. Risk of hospitalization and deaths 30 days after down-titration was estimated after adjusting for congestion level. At baseline the cohort consisted mostly of males (59%), with a mean age of 77 years. Patients were highly symptomatic with 76% classified as New York Heart Association class III or IV. Within 30 days after a down-titration, diuretic dose necessitated an increase in 30.4% of cases, compared with 20.7% following up-titration and 8.0% on a stable dose. Hospitalization and death were significantly more frequent following down-titration (3.4% and 2% within 30 days, respectively) than with a stable dose (1% and 0.6%, p < 0.001). Similar hospitalization rates were observed after up-titration. The risk of hospitalization doubled and of death tripled after down-titration in patients with similar congestion levels. Conclusions: There is a significant risk that reduction in diuretic dose requires restart or increase of diuretics within a short period. Additionally, there may be a significant risk associated with diuretic dose reduction. Therefore, HF patients need to be closely monitored after down-titration of loop diuretic therapy.

19 September 2023 in ESC Heart Failure
Verified
Journal Article
Open access
Jerremy WeertsJerremy Weerts
Jerremy Weerts
HAHesam Amin
Hesam Amin
AAArantxa Barandiarán Aizpurua
Arantxa Barandiarán Aizpurua
AGAndreas B. Gevaert
Andreas B. Gevaert
MHM. Louis Handoko
M. Louis Handoko
VEVanessa P.M. van Empel
Vanessa P.M. van Empel
Aims: Diagnosis of heart failure with preserved ejection fraction (HFpEF) can be challenging. This study aimed to evaluate the potential of a webtool to enhance the scoring accuracy when applying the complex HFA-PEFF and H2FPEF algorithms, which are commonly used for diagnosing HFpEF. Methods and results: We developed an online tool, the HFpEF calculator, that enables the automatic calculation of current HFpEF algorithms. We assessed the accuracy of manual vs. automatic scoring, defined as the percentage of correct scores, in a cohort of cardiologists with varying clinical experience. Cardiologists scored eight online clinical cases using a triple cross-over design (i.e. two manual–two automatic–two manual–two automatic). Data were analysed in study completers (n = 55, 29% heart failure specialists, 42% general cardiologists, and 29% cardiology residents). Manually calculated scores were correct in 50% (HFA-PEFF: 50% [50–75]; H2FPEF: 50% [38–50]). Correct scoring improved to 100% using the HFpEF calculator (HFA-PEFF: 100% [88–100], P < 0.001; H2FPEF: 100% [75–100], P < 0.001). Time spent on clinical cases was similar between scoring methods (±4 min). When corrections for faulty algorithm scores were displayed, cardiologists changed their diagnostic decision in up to 67% of cases. At least 67% of cardiologists preferred using the online tool for future cases in clinical practice. Conclusions: Manual calculation of HFpEF diagnostic algorithms is often inaccurate. Using an automated webtool to calculate HFpEF algorithms significantly improved correct scoring. This new approach may impact the eventual diagnostic decision in up to two-thirds of cases, supporting its routine use in clinical practice.